Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer

Author： Scott Sarah M   Brown Myles   Come Steven E  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.5, 2011-09, pp. : 819-826

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health

By Journé Fabrice   Body Jean-Jacques   Leclercq Guy   Laurent Guy  

Expert Opinion on Drug Safety, Vol. 7, Iss. 3, 2008-05 ,pp. : 241-258

Informa Healthcare

Access to resources Recommend Favorite

Fulvestrant: A Review of its Use in Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women with Disease Progression following Antiestrogen Therapy

By McKeage K.   Curran M.P.   Plosker G.L.  

Drugs, Vol. 64, Iss. 6, 2004-01 ,pp. : 633-648

Adis International

Access to resources Recommend Favorite

Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer

By Robertson J.F.R.  

Clinical Pharmacokinetics, Vol. 43, Iss. 8, 2004-01 ,pp. : 529-538

Adis International

Access to resources Recommend Favorite

Fulvestrant as EFECTive as exemestane in advanced breast cancer

By  

Inpharma, Vol. 1, Iss. 1570, 2007-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Fulvestrant: benefits at acceptable costs in advanced breast cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 571, 2009-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite